To examine psychiatric-related health care costs and inpatient utilization among patients with type I bipolar disorder who relapse frequently within a large Medicaid database. METHODS: A large multistate Medicaid claims database (MarketScan ® ) was used to identify patients aged 18 to 64 years with type I bipolar disorder; ≥1 prescription claim for lithium, an anticonvulsant, or an antipsychotic between January 1, 2004 and December 31, 2005; and ≥24 months' continuous enrollment. Frequent relapse (FR) was defined as ≥2 clinically significant events (CSEs) occurring during a 12-month identification period beginning with the initial CSE (if any). CSEs included emergency room (ER) visits or inpatient hospitalizations (IH) with a principal diagnosis of bipolar disorder or a change in bipolar disorder medication(s). Patients were followed for a subsequent 12-month period to evaluate health care utilization and associated costs. Generalized linear modeling was used to estimate the impact of FR on psychiatric-related health care costs; logistic regression was used to estimate the impact of FR on psychiatric IH and ER visits. RESULTS: Of 5527 patients with type I bipolar disorder, 53% relapsed frequently. Of the patients with FR, 75% were female. Close to one-third (29%) of patients who relapsed frequently in the identification period also relapsed frequently in the follow-up period. During the 12-month follow-up period, patients with FR had higher adjusted per-patient psychiatric-related health care costs (mean $6014 vs $3495; P < 0.001), 3.7 times greater odds of psychiatric IH (P < 0.01), and 3.1 times greater odds of psychiatric-related ER visits (P < 0.01) than patients who did not relapse frequently. CONCLUSIONS: Medicaid patients with type I bipolar disorder who relapsed frequently had significantly higher adjusted psychiatric-related health care costs and greater odds of IH and ER events in a subsequent period than patients who did not relapse frequently. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC. Retrospective cohort analysis of multistate Medicaid patients who were aged ≥18 years, had ≥1 inpatient or ≥2 outpatient medical claims indicating bipolar I disorder (ICD-9-CM codes 296.0X-296.1X, 296.4X-296.7X), and filled ≥1 prescription for an antipsychotic medication between January 1, 2004, and December 31, 2006. Patients were followed for 1 year from the date of first, or index, antipsychotic prescription. Patients were required to be continuously eligible for Medicaid without dual Medicare eligibility from 1 year before (baseline) through 1 year after (follow-up) index, and were required to receive ≥1 additional antipsychotic claim during follow-up to ensure a treated population. Descriptive statistics were generated on the use and costs (proxied by Medicaid payments) of hospitalizations and ER visits, both all-cause and psychiatric-related (ICD-9-CM 290.XX-319.XX). RESULTS: 9410 patients met study eligibility criteria. Mean (±SD) patient age was 38.0 (±11.9) years, 74% were female, and 75% were white. Approximately 31% and 57% had preexisting diagnoses of substance abuse and psychiatric conditions, respectively. During follow-up, 40% of patients were hospitalized for any reason (37% with a psychiatric diagnosis). Patients had an average (±SD) of 0.9 (±1.7) all-cause and 0.8 (±1.6) psychiatric-related hospitalizations. All-cause and psychiatric-related ER visits occurred in 67% and 29% of patients, with an average (±SD) of 6.1 (±10.9) and 0.9 (±2.7) visits per patient, respectively. Average (±SD) costs were $6986 (±$10,374) and $6916 (±$10,288) for all-cause and psychiatric-related hospitalizations, and $158 (±$218) and $256 (±$416) for all-cause and psychiatric-related ER visits, respectively. CONCLUSIONS: Hospitalizations, ER visits, and costs were substantial among patients with bipolar I disorder. Studies investigating predictors of hospitalizations and ER visits in this patient population are warranted. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC.
PMH58 ASSESSMENT OF HEALTH CARE UTILIZATION AND COST AMONG PATIENTS WITH BIPOLAR I DISORDER TREATED WITH ANTIPSYCHOTIC THERAPY IN A MULTISTATE MEDICAID POPULATION
Lang K 1 , Abouzaid S 2 , Muser E 3 , Sikirica M 4 , Korn JR 1 , Dirani R 2 , Menzin J 1 1 Boston Health Economics, Inc, Waltham, MA, USA, 2 Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 3 Ortho-McNeil Janssen Scientific Affairs, LLC, O'Fallon, MO, USA, 4 Ortho-McNeil Janssen Scientific Affairs, LLC, Bethesda, MD, USA OBJECTIVES: To estimate the rates and costs of all-cause and psychiatric-related hospitalizations and ER visits among patients with bipolar I disorder. METHODS: Retrospective cohort analysis of multistate Medicaid patients who were aged ≥18 years, had ≥1 inpatient or ≥2 outpatient medical claims indicating bipolar I disorder (ICD-9-CM codes 296.0X-296.1X, 296.4X-296.7X), and filled ≥1 prescription for an antipsychotic medication between January 1, 2004, and December 31, 2006. Patients were followed for 1 year from the date of first, or index, antipsychotic prescription. Patients were required to be continuously eligible for Medicaid without dual Medicare eligibility from 1 year before (baseline) through 1 year after (follow-up) index, and were required to receive ≥1 additional antipsychotic claim during follow-up to ensure a treated population. Descriptive statistics were generated on the use and costs (proxied by Medicaid payments) of hospitalizations and ER visits, both all-cause and psychiatric-related (ICD-9-CM 290.XX-319.XX). RESULTS: 9410 patients met study eligibility criteria. Mean (±SD) patient age was 38.0 (±11.9) years, 74% were female, and 75% were white. Approximately 31% and 57% had preexisting diagnoses of substance abuse and psychiatric conditions, respectively. During follow-up, 40% of patients were hospitalized for any reason (37% with a psychiatric diagnosis). Patients had an average (±SD) of 0.9 (±1.7) all-cause and 0.8 (±1.6) psychiatric-related hospitalizations. All-cause and psychiatric-related ER visits occurred in 67% and 29% of patients, with an average (±SD) of 6.1 (±10.9) and 0.9 (±2.7) visits per patient, respectively. Average (±SD) costs were $6986 (±$10,374) and $6916 (±$10,288) for all-cause and psychiatric-related hospitalizations, and $158 (±$218) and $256 (±$416) for all-cause and psychiatric-related ER visits, respectively. CONCLUSIONS: Hospitalizations, ER visits, and costs were substantial among patients with bipolar I disorder. Studies investigating predictors of hospitalizations and ER visits in this patient population are warranted. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC. PMH59 SYSTEM DYNAMICS SIMULATION FOR ACUTE SCHIZOPHRENIA TREATMENT Nakahara N 1 , Kobayashi M 2 , Mano T 3 , Nakamura J 4 1 Eli Lilly Japan, Kobe, Japan, 2 Crecon Research & Consulting Inc., Tokyo, Japan, 3 Tama University of Medical Risk management Center, Tokyo, Japan, 4 University of Occupational and Environmental Health, Kitakyushu, Japan OBJECTIVES: It is important for the management of a psychiatric hospital having an acute-care ward to estimate medical practice revenues under different conditions. We developed a system dynamics (SD) simulation model for the treatment of acute schizophrenia to investigate the effect of the treatment of patients with acute schizophrenia on the hospital management. METHODS: We developed an SD simulation model for patient admission and discharge at a psychiatric acute-care ward. The model assumed an imaginary, newly built psychiatric hospital consisting of 3 types of wards: a psychiatric acute-care ward, a general psychiatric ward, and a psychiatric nursing-care ward. The rates of discharge were set at 40%/month, 30%/month and 20%/month for a psychiatric acute-care ward, a general psychiatric ward, and a psychiatric nursing-care ward, respectively. The number of newly admitted patients was supposed to be 10 per month. We compared the total medical practice revenues at 36 months. RESULTS: Up to 9 months of outpatient treatment, the total medical practice revenues increased and then decreased at 12 months. A 2-way sensitivity analysis on the firsttime admissions and the duration of outpatient treatment revealed that the total medical practice revenues were higher when the number of newly admitted patients was 5-11 at 9 months of outpatient management; however, when the number of newly admitted patients was 12-15, the maximum medical practice revenue was obtained at 12 months of outpatient management. CONCLUSIONS: Total medical practice revenues change depending on the rates of discharge from a psychiatric acute-care ward, the duration of outpatient treatment and the number of newly admitted patients. A budget plan for each psychiatric hospital having a psychiatric acute-care ward should be based on the calculation of those parameters and a systematic approach to patient management is important.
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PMH60 ADHERENCE TO MEDICATION FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD):DOES THE TIMEFRAME MATTER?
Barner JC, Khoza S, Oladapo A The University of Texas at Austin, Austin, TX, USA OBJECTIVES: ADHD medication users frequently take 'drug holidays' during the summer months. The study objective was to compare ADHD medication adherence for an entire year (EY-365 days) and the school year (SY-270 days) by medication class and type. METHODS: Continuously enrolled Texas Medicaid children (≤18 years) who had ≥2 prescription claims for an ADHD medication served as the study population. EY and SY (September 1-May 31) prescription claims were extracted from July 2002-December 2008. Prescription claims were grouped by medication class [immediate release(IR), extended release(ER), long-acting(LA), non-stimulant(NS)]; and medication type [stimulant(S) vs. non-stimulant(NS)]. Adherence, assessed by medication possession ratio (MPR) using a fixed interval denominator, was measured both continuously and dichotomously (80%). T-tests, ANOVAs and chi-square were employed to determine differences between groups. RESULTS: Overall mean adherence for EY (n = 62,789) was 49.8 ± 30.3 and SY (n = 50,842) was 62.2 ± 26.2. For EY, mean medication class adherence was not significantly different between NS (52.5 ± 30.9) and ER (52.1 ± 30.2); however, LA (47.6 ± 30.9) and IR (37.2 ± 27.1) were significantly lower (p < 0.0001). Regarding SY, adherence was not significantly different among ER (63.7 ± 26.0), LA (63.5 ± 23.8) and NS (62.9 ± 27.0), while IR (52.8 ± 24.7) was significantly lower (p < 0.0001). When adherence was dichotomized, EY medication class adherence differed significantly (p < 0.0001): NS(25.8%), ER(24.1%), LA(21.2%), IM(9.8%). Similarly, SY differed significantly (p < 0.0001): NS(30.8%), ER(30.0%), LA(25.6%), IM(16.2%). NS had significantly higher mean adherence than S, respectively: EY(52.5 ± 30.9 vs. 49.4 ± 30.2; p < .0001) and SY(62.9 ± 27.0 vs. 62.1 ± 26.1; p < .01). When dichotomized, results were similar (p < .0001): EY(25.8% vs. 21.5%) and SY(30.8% vs. 27.9%). CONCLUSIONS: Subjects were more adherent during SY compared to EY. Medication class mean adherence differed depending on timeframe used. For analyses comparing NS and S, NS had significantly higher adherence, however for SY mean adherence, the difference may not be practically significant. Due to unique patient medication-taking behaviors, ADHD medication adherence differs depending on the timeframe used.
